The roles and therapeutic potential of cyclin-dependent kinases (CDKs) in sarcoma.

Cancer Metastasis Rev 2016 06;35(2):151-63

Department of Orthopaedic Surgery, Sarcoma Biology Laboratory, Massachusetts General Hospital and Harvard Medical School, 55 Fruit Street, Jackson 1115, Boston, MA, 02114, USA.

Uncontrolled proliferation and cell growth is the hallmark of many different malignant diseases, including sarcomas. Cyclin-dependent kinases (CDKs) are members of the serine/threonine protein kinase family and play crucial roles in tumor cell proliferation and growth by controlling cell cycle, transcription, and RNA splicing. In addition, several CDKs influence multiple targets and phosphorylate transcription factors involved in tumorigenesis. There are many examples linking dysregulated activation and expression of CDKs to tumors, and targeting CDKs in tumor cells has become a promising therapeutic strategy. More recently, the Food and Drug Administration (FDA) has approved the CDK4/6 inhibitor palbociclib for treating metastatic breast cancer. In sarcomas, high levels of CDK mRNA and protein expression have been found in most human sarcoma cells and patient tissues. Many studies have demonstrated consistent results in which inhibition of different CDKs decrease sarcoma cell growth and induce apoptosis. Therefore, CDKs comprise an attractive set of targets for novel anti-sarcoma drug development. In this review, we discuss the roles of different members of CDKs in various sarcomas and provide a pre-clinical overview of promising therapeutic potentials of targeting CDKs with a special emphasis on sarcoma.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10555-015-9601-1DOI Listing
June 2016
28 Reads

Publication Analysis

Top Keywords

cdks
9
kinases cdks
8
cell growth
8
promising therapeutic
8
cyclin-dependent kinases
8
targeting cdks
8
demonstrated consistent
4
examples linking
4
tumorigenesis examples
4
consistent inhibition
4
inhibition cdks
4
involved tumorigenesis
4
studies demonstrated
4
linking dysregulated
4
activation expression
4
expression cdks
4
patient tissues
4
dysregulated activation
4
tissues studies
4
factors involved
4

References

(Supplied by CrossRef)

Z Burningham et al.
Clinical sarcoma research 2012

M Malumbres et al.
Nature Reviews Cancer 2009

L Yamasaki et al.
Cancer Treatment and Research 2003

S Larochelle et al.
Nature Structural & Molecular Biology 2012

D Hu et al.
The Journal of Biological Chemistry 2003

V Krystof et al.
Current Drug Targets 2010

RP Fisher et al.
Journal of Cell Science 2005

A Besson et al.
Developmental Cell 2008

L L’Italien et al.
Cell cycle (Georgetown, Tex) 2006

D Mao et al.
The Journal of Biological Chemistry 2010

Similar Publications